Search results
Results from the WOW.Com Content Network
A recall has been ordered for a high-profile diabetes drug after producers discovered it contained alarmingly high levels of a cancer-causing impurity. Marksans Pharma Limited has recalled ...
Heads up, consumers: A diabetes drug is facing recall because the medication contains excess levels of a cancer-causing agent, the U.S. Food and Drug Administration (FDA) announced this week.
Metformin also has significant effects on the gut microbiome, such as its effect on increasing agmatine production by gut bacteria, but the relative importance of this mechanism compared to other mechanisms is uncertain. [126] [127] [128] Due to its effect on GLUT4 and AMPK, metformin has been described as an exercise mimetic. [129] [130]
This list is not limited to drugs that were ever approved by the FDA. Some of them (lumiracoxib, rimonabant, tolrestat, ximelagatran and ximelidine, for example) were approved to be marketed in Europe but had not yet been approved for marketing in the US, when side effects became clear and their developers pulled them from the market.
The U.S. is on track to issue a record number of recalls this year. USA TODAY's recalls database shows you what products should be tossed.
Yes, metformin treatment has been shown to lower risk of heart-related events in people with type 2 diabetes by improving blood fat levels, reducing inflammation, and lowering blood pressure ...
It was sold nationwide by a New Jersey firm.
“It has been shown to lower the risk of death from cardiovascular disease in patients with T2DM.” ... “If you have type 2 diabetes and metformin is not working for you, speak to your doctor ...